Advertisement

International Journal of Legal Medicine

, Volume 118, Issue 6, pp 326–331 | Cite as

Development of a psilocin immunoassay for serum and blood samples

  • C. Albers
  • H. Köhler
  • M. Lehr
  • B. Brinkmann
  • J. Beike
Original Article

Abstract

After the immunisation of rabbits with a psilocin-specific immunogen, polyclonal antisera were obtained. With these antisera a competitive, heterogeneous radioimmunoassay for the detection of psilocin was developed. As tracer a derivative of psilocin was synthesised, which contained a tritiated CH3 group. The antisera showed a specific reaction with psilocin. The cross-reactivity of structurally related endogenous substances like serotonin, tryptophan and tyrosine was below 0.01%. Also common drugs of abuse (Δ9-tetrahydrocannabinol, cocaine, morphine, amphetamine) showed negligible cross-reactivity (0.01–2%). Only tricyclic neuroleptics with a (dimethylamino)ethyl side-chain showed some cross-reactivity (20%). Spiked serum and blood samples were analysed with this new immunoassay and the results obtained were compared with the values measured with a validated GC-MS method.

Keywords

Psilocin Radioimmunoassay GC-MS 

Notes

Acknowledgement

The authors wish to thank Dr. W. Schneider and the staff from Dade Behring GmbH Marburg who were responsible for the animal experimental section.

References

  1. 1.
    Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol 7:357–364CrossRefPubMedGoogle Scholar
  2. 2.
    Horita A, Weber LJ (1961) The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates. Biochem Pharmacol 7:47–54CrossRefPubMedGoogle Scholar
  3. 3.
    Horita A, Weber LJ (1962) Dephosphorylation of psilocybin in the intact mouse. Toxicol Appl Pharmacol 4:730–737PubMedGoogle Scholar
  4. 4.
    Kalberer F, Kreis W, Rutschmann J (1962) The fate of psilocin in the rat. Biochem Pharmacol 11:261–269CrossRefPubMedGoogle Scholar
  5. 5.
    Hasler F, Bourquin D, Brenneisen R, Baer T, Vollenweider FX (1997) Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharma Acta Helv 72:175–184CrossRefGoogle Scholar
  6. 6.
    Sticht G, Käferstein H (2000) Detection of psilocin in body fluids. Forensic Sci Int 113:403–407CrossRefPubMedGoogle Scholar
  7. 7.
    Kysilka R (1990) Determination of psilocin in rat urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr 534:287–290CrossRefPubMedGoogle Scholar
  8. 8.
    Lindenblatt H, Kramer E, Holzmann-Erens P, Gouzoulis-Mayfrank E, Kovar K-A (1998) Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated online solid-phase extraction. J Chromatogr B Biomed Sci Appl 709:255–263CrossRefPubMedGoogle Scholar
  9. 9.
    Grieshaber AF, Moore KA, Levine B (2001) The detection of psilocin in human urine. J Forensic Sci 46:627–630PubMedGoogle Scholar
  10. 10.
    Bogusz MJ (2000) Liquid chromatography-mass spectrometry as a routine method in forensic sciences: a proof of maturity. J Chromatogr B Biomed Sci Appl 748:3–19CrossRefPubMedGoogle Scholar
  11. 11.
    Kamata T, Nishikawa M, Katagi M, Tsuchihashi H (2003) Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 792:421–427Google Scholar
  12. 12.
    Sagawa K, Kimura A, Saito Y (2003) Production and characterization of a monoclonal antibody for sweat-specific protein and its application for sweat identification. Int J Legal Med 117:90–95PubMedGoogle Scholar
  13. 13.
    Pavlic M, Haidekker A, Grubwieser P (2002) Fatal accident caused by isoflurane abuse. Int J Legal Med 116:357–360PubMedGoogle Scholar
  14. 14.
    Albers C, Lehr M, Beike J, Kohler H, Brinkmann B (2002) Synthesis of a psilocin hapten and a protein-hapten conjugate. J Pharm Pharmacol 54:1265–1270CrossRefPubMedGoogle Scholar
  15. 15.
    Nichols DE, Frescas S (1999) Improvements to the synthesis of psilocybin and a facile method for preparing the O-acetal prodrug of psilocin. Synthesis 6:935–938CrossRefGoogle Scholar
  16. 16.
    Yamada F, Tamura M, Somei M (1998) A facile synthesis of psilocin from indole-3-carbaldehyde. Heterocycles 49:451–457Google Scholar
  17. 17.
    Abraham GE (1969) Solid phase radioimmunoassay of estradiol-17 beta. J Clin Endocrinol Metab 29:866–870PubMedGoogle Scholar
  18. 18.
    Troxler F, Seemann F, Hofmann A (1959) Synthetic indole compounds. II. Psilocybin and psilocin modifications. Helv Chim Acta 42:2073–2103Google Scholar
  19. 19.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Medicine CfV (2001) Guidance for industry. Bioanalytical validationGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • C. Albers
    • 1
  • H. Köhler
    • 2
  • M. Lehr
    • 1
  • B. Brinkmann
    • 2
  • J. Beike
    • 2
  1. 1.Institute of Pharmaceutical and Medicinal ChemistryUniversity of MünsterMünsterGermany
  2. 2.Institute of Legal MedicineUniversity Hospital Münster MünsterGermany

Personalised recommendations